Palatin Technologies, Inc.
(NYSE Amex Equities : PTN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
JNJJohnson & Johnson 0.02%178.330.7%$1352.13m
MRKMerck & Co., Inc. -0.19%92.950.7%$1225.93m
PFEPfizer Inc. 0.95%53.250.9%$1142.39m
LLYEli Lilly & Co. -0.10%329.811.1%$1010.52m
BMYBristol-Myers Squibb Co. -0.94%75.511.0%$974.71m
ABBVAbbVie, Inc. -0.25%152.151.9%$958.17m
AZNAstraZeneca Plc 0.62%66.911.0%$470.25m
SGENSeagen Inc. 2.48%179.485.7%$331.92m
GSKGSK Plc 0.64%43.390.2%$274.62m
TPTXTurning Point Therapeutics, Inc. 0.11%75.260.0%$179.28m
NVSNovartis AG 0.82%84.420.2%$174.89m
HZNPHorizon Therapeutics Plc 1.69%83.865.4%$173.90m
ALNYAlnylam Pharmaceuticals, Inc. 1.59%152.398.1%$148.89m
NVONovo Nordisk A/S -0.49%109.950.1%$147.76m
MRTXMirati Therapeutics, Inc. -3.67%67.271.6%$133.81m

Company Profile

Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, a peptide melanocortin receptor 4 agonist for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.